Search

Delafloxacin

It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. … Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections,

Halothane

Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required.

Roquinimex

Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

Methoxsalen

It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.

Hydrocortisone butyrate

Hydrocortisone probutate

Zidesamtinib

of resistance mutations, particularly the solvent front G2032R substitution, and progression of disease in the brain. … Zidesamtinib is an orally administered ROS1 kinase inhibitor designed to remain active against ROS1 resistance mutations.

Prademagene zamikeracel

[L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

Ketamine

It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects.

Bleomycin

Bleomycin A2 is used as the representative structure for Bleomycin.